Lupin divests women's health specialty business in US to Evofem Biosciences for nearly $84 mn
Lupin announced on Monday that it has divested its US commercial women’s health specialty business to Evofem Biosciences, a US biopharmaceutical company focused exclusively on women’s health.
Lupin’s US Commercial Women’s Health Specialty Business is primarily focused on commercializing Solosec (secnidazole) 2g oral granules. This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.
Under the terms of the deal, Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones.
Dr. Fabrice Egros, President, Global Corporate Development, Lupin said, “We are very pleased to divest our U.S. Commercial Women’s Health Specialty business, including Solosec, to Evofem. This divestment is another step in aligning our U.S. specialty business with our strategic plan to build our specialty business in therapeutic areas where we have building blocks of synergy. These include respiratory and neurological diseases.”
“The acquisition of this commercial business aligns with and advances our mission to improve access to innovative and differentiated options that impact women’s daily lives. Solosec is a commercially attractive, single-dose oral antibiotic that addresses two pervasive sexual health infections. We can now fully leverage our commercial infrastructure, maximize our strong physician relationships, and re-launch an asset with tremendous growth
